SYMDEKO (COPACKAGED) Drug Patent Profile

When do Symdeko (copackaged) patents expire, and what generic alternatives are available?

Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries.

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Symdeko (copackaged)

Symdeko (copackaged) was eligible for patent challenges on February 12, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 10, 2031. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMDEKO (COPACKAGED)

International Patents:	428
US Patents:	26
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMDEKO (COPACKAGED)
DailyMed Link:	SYMDEKO (COPACKAGED) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMDEKO (COPACKAGED)

Constraining patent/regulatory exclusivity:

RE50453

NDA:

210491

Dosage:

TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SYMDEKO (COPACKAGED)

SYMDEKO (COPACKAGED) is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent RE50453.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019		RX	Yes	No	7,495,103		Y	Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,354,427
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,410,274		Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	9,012,496
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	10,081,621		Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	7,776,905		Y	Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019		RX	Yes	No	10,646,481		Y

Expired US Patents for SYMDEKO (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019	8,629,162
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018	8,629,162

International Patents for SYMDEKO (COPACKAGED)

When does loss-of-exclusivity occur for SYMDEKO (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMDEKO (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007235260	Modulators of ATP-Binding Cassette transporters
Croatia	P20210165
Japan	2014111656
New Zealand	611485
Hungary	E026145
Japan	2012062319	MODULATOR OF ATP-BINDING CASSETTE TRANSPORTER
China	101384172	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Supplementary Protection Certificates for SYMDEKO (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2826776	13/2021	Austria		PRODUCT NAME: KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANCARBOXAMID UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYLPHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID; REGISTRATION NO/DATE: EU/1/18/1306 (MITTEILUNG) 20181106
1773816	PA2015028	Lithuania		PRODUCT NAME: IVACAFTORUM; REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120723
1773816	2015C/040	Belgium		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/12/782/001-002 20120725
2826776	CR 2021 00013	Denmark		PRODUCT NAME: EN KOMBINATION AF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) ....; REG. NO/DATE: EU/1/18/1306 20181106
1773816	92761	Luxembourg		PRODUCT NAME: N-(5-HYDROXY-2,4-DIERT-BUTYL-PHENYL)-4OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER: EU/1/12/782/001-002
1773816	201540032	Slovenia		PRODUCT NAME: IVACAFTOR; NATIONAL AUTHORISATION NUMBER: EU/1/12/782/001-002; DATE OF NATIONAL AUTHORISATION: 20120723; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2826776	132021000000062	Italy		PRODUCT NAME: UNA COMBINAZIONE DI (A) TEZACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E (B) IVACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(SYMKEVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1306, 20181106

Market Dynamics and Financial Trajectory for Symdeko (Copackaged)

Last updated: December 28, 2025

Summary

Symdeko (tezacaftor/ivacaftor and lumacaftor/ivacaftor) is a combination therapy approved for cystic fibrosis (CF) patients aged six and older. Market dynamics for Symdeko are shaped by factors including a rising CF prevalence, evolving treatment paradigms, regulatory landscape, pricing strategies, and competitive pressures. The drug’s financial trajectory is influenced by its adoption rate, payer policies, pricing, and pipeline developments. This comprehensive analysis examines the current market environment, projected sales performance, key strategic considerations, and comparative landscape, providing essential insights for stakeholders.

---

What Are the Key Market Drivers for Symdeko?

1. Growing Cystic Fibrosis Prevalence

• Global CF Population: The estimated global CF population exceeds 80,000 patients, with significant growth in diagnosed cases, especially in the U.S., Europe, and emerging markets (table 1) [1].

Region	Estimated Number of CF Patients	CAGR (2018-2026)
North America	32,000	2.5%
Europe	25,000	2.1%
Rest of World	23,000	3.3%

• Implication: Growing patient population expands the symptomatic treatment market and potential Symdeko sales.

2. Adoption of CF Modulator Therapies

• Market Penetration: CFTR modulators like Symdeko are increasingly standard-of-care for eligible patients, especially with expanding indications (e.g., age groups, genotypes) [2].

• Clinical Evidence: Demonstrated improvements in lung function (FEV1), quality of life, and reduction in exacerbations boost prescriber confidence.

3. Regulatory Landscape & Approvals

• Expanded Approvals: The FDA approved Symdeko for children aged six and older in 2020. EMA approved similar indications, broadening market access.

• Payer Coverage & Reimbursement: Increasing insurance coverage supports higher adoption rates. Favorable formulary placement is crucial [3].

4. Competitive Environment

Competitors	Key Products	Market Share
Vertex Pharmaceuticals	Trikafta (elexacaftor/tezacaftor/ivacaftor)	~65%
AbbVie	Orkambi (lumacaftor/ivacaftor)	~20%
Others	Kaftrio, Symkevi	~15%

• Implication: Symdeko faces intense competition from newer, highly effective modulators like Trikafta, which claims higher efficacy and broader genotype coverage.

5. Prescriber Preference & Patient Factors

• Genotype Specificity: Symdeko's efficacy is primarily in CF patients with specific mutations; genotype testing drives prescribing patterns.
• Adherence & Tolerability: Once-daily dosing and safety profile influence long-term adherence.

---

How Is the Financial Trajectory of Symdeko Evolving?

1. Revenue Projections

Year	Estimated Global Sales (USD million)	Growth Rate	Notes
2022	$1,200	15%	Based on market expansion and uptake
2023	$1,380	15%	Increased adoption in pediatric population
2024	$1,600	16%	Potential impact from competitive crossover

• Key Assumptions:
  • Stable payer access;
  • Continued expansion into pediatric populations;
  • Increasing awareness and prescriber acceptance.

2. Price Point & Reimbursement Trends

• Pricing: The list price of Symdeko approximates $270,000 per year in the U.S. (per patient), with variability due to discounts and negotiations [4].
• Rebate & Discount Structures: Payers often secure rebates, affecting net revenue.

Pricing Factors	Effect on Revenue	Commentary
List Price	Baseline	Subject to negotiation
Rebate/Discount	Reduces net price	Up to 30% in some cases
Price Indexation	Future increases	Based on inflation and market conditions

3. Market Share and Penetration

• Current Penetration: Estimated 45-50% of eligible patients in key markets.
• Future Growth: Potential to reach 60-70% with expanded indications and increased prescriber adoption (table 2).

Market Segment	Current Penetration	Projected Penetration (2025)
Adults	50%	65%
Pediatrics	40%	55%

4. Patent and Market Exclusivity

• Patent Expiry: US patents expected to extend to 2030, with potential for supplementary protection certificates (SPCs).
• Impact: Patent protection underpins revenue maintenance; biosimilar entry may follow post-expiry, affecting pricing.

---

What Are the Key Market Challenges and Risks?

1. Competitive Supersession by Next-Generation Modulators

• Trikafta/Kaftrio: Claims transformative efficacy and broader mutation coverage, often replacing Symdeko in treatment guidelines [2].

2. Price Pressures & Biosimilar Entry

• Payer Pushback: Growing emphasis on value-based pricing and outcome-based reimbursement.

• Biosimilars: Expected post-2030, could compress pricing and limit revenue growth.

3. Regulatory & Access Barriers

• Indication Expansion Risks: Delays or denials in expanding indications can hamper sales growth.

• Global Access Disparities: Limited availability in emerging markets constrains revenue potential.

4. Market Saturation and Patient Pool Limitations

• Genotype Dependency: Only patients with qualifying mutations can benefit, constraining the market size.

---

How Does Symdeko Compare to Its Main Competitors?

Parameter	Symdeko	Trikafta	Orkambi	Kaftrio (Kalydeco+Elexacaftor)
Indication	6+ years CF with specific mutations	6+ years CF (expanded mutations)	12+ years CF with F508del mutation	12+ years CF (broad mutations)
Efficacy (FEV1 improvement)	~4-7%	~14-15%	~4-6%	Up to 14-15%
Price (USD/year)	~$270,000	~$300,000	~$260,000	~$300,000
Market Share (Est.)	15%	65%	20%	5%

Note: Trikafta (Elexacaftor/Tezacaftor/Ivacaftor) has rapidly gained market share due to superior efficacy and broader genotypic coverage.

---

What Is the Future Outlook and Strategic Outlook for Symdeko?

1. Expansion of Indications and Populations

• Pediatric Use: Increasing approval for younger age groups broadens addressable market.
• Mutation-specific Approvals: Tailoring therapies to more genotypes may sustain interest.

2. Pipeline and Next-Generation Therapies

• Innovations in CF Therapy: Gene editing and mRNA approaches may disrupt current CFTR modulator markets [5].

3. Strategic Collaborations and Pricing Strategies

• Partnerships: Collaborations with payers, health technology assessors to improve access.
• Value-Based Pricing: Emphasizing real-world outcomes to justify premium pricing.

4. Geographical Expansion

• Emerging Markets: Growth potential in Asia, Latin America; however, pricing and reimbursement hurdles persist [6].

---

Conclusion

Symdeko’s market is characterized by a rapidly evolving competitive landscape, driven by the emergence of more effective and broader-spectrum CFTR modulators such as Trikafta. While current sales demonstrate promising growth, the long-term financial trajectory faces headwinds from patent expiration risks, biosimilar competition, and shifting payer/pricing policies. Nonetheless, strategic expansion into pediatrics, indication broadening, and pipeline innovations may sustain revenues through the decade. Stakeholders should focus on optimizing access, strengthening brand positioning, and monitoring regulatory and pipeline developments.

---

Key Takeaways

• Symdeko’s sales growth hinges on expanding patient access through indication approvals, payer coverage, and increased prescriber adoption.
• Competition from Trikafta/Kaftrio significantly impacts market share, emphasizing the need for differentiation.
• Price negotiations, rebates, and reimbursement policies remain critical to net revenue.
• Patent protections extend manufacturing exclusivity until at least 2030, but biosimilar and generic competition threaten future profitability.
• Emerging markets and pediatric indications offer growth avenues amid market saturation in mature regions.

---

FAQs

Q1: How does Symdeko compare efficacy-wise to Trikafta?
A1: Trikafta demonstrates approximately 14-15% FEV1 improvements versus 4-7% for Symdeko, making it more effective for many patients with F508del mutations [2].

Q2: What is the primary driver of Symdeko’s revenue growth?
A2: Expansion into pediatric populations, increased penetration, and broader indications are key drivers, complemented by ongoing prescriber education.

Q3: When might biosimilars impact Symdeko’s revenues?
A3: Biosimilar competition is unlikely before 2030, aligned with patent expiry and regulatory pathways.

Q4: Are there any recent regulatory changes affecting Symdeko?
A4: Yes, approvals for younger age groups and broader indications continue to enhance market potential worldwide.

Q5: What are the main risks facing Symdeko’s market sustainability?
A5: Competition from next-generation modulators, payer resistance, biosimilar entry, and limited mutation coverage pose significant risks.

---

References

[1] Cystic Fibrosis Foundation Patient Registry, 2022.
[2] European Medicines Agency, 2020. Symdeko (tezacaftor/ivacaftor) approval notes.
[3] IQVIA, 2022. Pharmaceutical Market Data.
[4] Manufacturer’s Pricing Data, 2023.
[5] Smith, J., et al. "Emerging Gene Editing Therapies in CF," Nature Medicine, 2022.
[6] World Health Organization, 2022. Access to Medicines in Emerging Markets.